Skip to main contentSkip to search and navigation

UEF eREPOSITORY

    • English
    • suomi
  • English 
    • English
    • suomi
  • Login
View Item 
  •   Home
  • Artikkelit
  • Terveystieteiden tiedekunta
  • View Item
  •   Home
  • Artikkelit
  • Terveystieteiden tiedekunta
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Evaluation of FASN inhibitors by a versatile toolkit reveals differences in pharmacology between human and rodent FASN preparations and in antiproliferative efficacy in vitro vs. in situ in human cancer cells

Thumbnail
Files
Article (1.961Mb)
Self archived version
final draft
Date
2020
Author(s)
Singha, Prosanta
Mäklin, Kiira
Vihavainen, Taina
Laitinen, Tuomo
Nevalainen, Tapio
Patil, Mahadeo
Tonduru, Arun
Poso, Antti
Laitinen, Jarmo
Savinainen, Juha
Unique identifier
10.1016/j.ejps.2020.105321
Metadata
Show full item record
More information
Research Database SoleCris

Self-archived article

Citation
Singha, Prosanta. Mäklin, Kiira. Vihavainen, Taina. Laitinen, Tuomo. Nevalainen, Tapio. Patil, Mahadeo. Tonduru, Arun. Poso, Antti. Laitinen, Jarmo. Savinainen, Juha. (2020). Evaluation of FASN inhibitors by a versatile toolkit reveals differences in pharmacology between human and rodent FASN preparations and in antiproliferative efficacy in vitro vs. in situ in human cancer cells.  European journal of pharmaceutical sciences, 149, 105321. 10.1016/j.ejps.2020.105321.
Rights
© 2020 Elsevier B.V.
Licensed under
CC BY-NC-ND https://creativecommons.org/licenses/by-nc-nd/4.0/
Abstract

De novo synthesis of fatty acids is essential to maintain intensive proliferation of cancer cells. Unlike normal cells that utilize food-derived circulating lipids for their fuel, cancer cells rely on heightened lipogenesis irrespective of exogenous lipid availability. Overexpression and activity of the multidomain enzyme fatty acid synthase (FASN) is crucial in supplying palmitate for protumorigenic activity. Therefore, FASN has been proposed as an attractive target for drug development. As an effort to set up an effective toolkit to study FASN inhibitors in human and rodent tissues, we validated activity-based protein profiling (ABPP) as a viable approach to unveil inhibitors targeting FASN thioesterase domain (FASN-TE). ABPP was combined with multi-well plate-assays designed for classical substrate-based FASN activity analysis together with powerful monitoring of cancer cell proliferation using IncuCyte® Live Cell Analyzing System. FASN-TE inhibitors were identified by competitive ABPP using HEK293 cell lysates in a screen of in-house compounds (200+) designed to target serine hydrolase (SH) family. The identified compounds were tested for their inhibitor potencies in vitro using a substrate-based activity assay monitoring FASN-dependent NADPH consumption in LNCaP prostate cancer cell preparation, in parallel with selected reference inhibitors, including orlistat (THL), GSK2194069, GSK837149A, platensimycin and BI-99179. LNCaP lysate supernatant was validated as a reliable native preparation to monitor FASN-dependent NADPH consumption as opposed to human glioma GAMG cells, whereas FASN enrichment was a prerequisite for accurate assays. While inhibitor pharmacology was identical between human prostate and glioma cancer cell FASN preparations, notable differences were revealed between human and rodent FASN preparations, especially for inhibitors targeting FASN-TE. ABPP combined with substrate-based assays facilitated identification of pan thiol-reactive inhibitor scaffolds, exemplified by the 1,2,4-thiadiazole moiety. Finally, selected compounds were evaluated for their antiproliferative efficacy in situ using GAMG cells. These studies revealed that while the tested compounds acted as potent FASN inhibitors in vitro, only a few showed antiproliferative efficacy in situ. To conclude, we describe a versatile toolkit to study FASN inhibitors in vitro and in situ using human cancer cells and reveal dramatic pharmacological differences between human and rodent FASN preparations.

Subjects
fatty acid synthesis   inhibition   cancer   glioma   anti-proliferation   pan-assay interfering compounds (PAINs)   
URI
https://erepo.uef.fi/handle/123456789/8166
Link to the original item
http://dx.doi.org/10.1016/j.ejps.2020.105321
Publisher
Elsevier BV
Collections
  • Terveystieteiden tiedekunta [1336]
University of Eastern Finland
OpenAccess
eRepo
erepo@uef.fi
UEF Open Science
Accessibility in eRepo
Service provided by
the University of Eastern Finland Library
Library web pages
Twitter
Facebook
Youtube
Library blog
 sitemap
Search

Browse

All of the ArchiveResource types & CollectionsBy Issue DateAuthorsTitlesSubjectsFacultyDepartmentFull organizationSeriesMain subjectThis CollectionBy Issue DateAuthorsTitlesSubjectsFacultyDepartmentFull organizationSeriesMain subject

My Account

Login
University of Eastern Finland
OpenAccess
eRepo
erepo@uef.fi
UEF Open Science
Accessibility in eRepo
Service provided by
the University of Eastern Finland Library
Library web pages
Twitter
Facebook
Youtube
Library blog
 sitemap